A small molecule that was earlier believed to have anti-fat and anti-cancer abilities, has now also proved its potential in putting off fat-making genes, say researchers at Baylor College of Medicine.
Such action in mice genetically prone to obesity causes the animals to become leaner, they say.
The researchers have also found the molecule to lowers the amount of fat in the mice's livers, along with their blood sugar and cholesterol levels.
"We are frankly very excited about it. It goes to the origin of [fat synthesis] - all the way back to gene expression," said Salih Wakil at Baylor.
Unlike cholesterol-lowering statins in use today, which block a single enzyme in the pathway, the chemical the researchers call fatostatin, "hits fat from the very beginning," said Motonari Uesugi.
As a result, fatostatin influences many of the genes involved in fat production and in various aspects of metabolic syndrome - a collection of risk factors including obesity, high cholesterol and insulin resistance - in one go.
Studies in cell culture showed that fatostatin, previously known only as 125B11, significantly lowers the activity of 63 genes, including 34 directly associated with fatty acid or cholesterol synthesis.
Many of these genes were known to be under the control of SREBP - a transcription factor which act as a well-known master controller of fat synthesis.
After more detailed analysis, the researchers found that the drug candidate blocked SREBP by preventing it from becoming active and entering the nucleus, where it would otherwise switch on the fat-making program.